A Three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4784-4793

  Saito, Motonobu ^a,b   Shiraishi, Kouya ^a   Matsumoto, Kenji ^c   Schetter, Aaron J ^d   Ogata Kawata, Hiroko ^a   Tsuchiya, Naoto ^a   Kunitoh, Hideo ^e   Nokihara, Hiroshi ^e   Watanabe, Shun Ichi ^e   Tsuta, Koji ^e   Kumamoto, Kensuke ^b   Takenoshita, Seiichi ^b   Yokota, Jun ^a,f   Harris, Curtis C ^d   Kohno, Takashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f Institute of Predictive and Personalized Medicine of Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MIRN1290 MICRORNA, HUMAN; MIRN135 MICRORNA, HUMAN; MIRN196 MICRORNA, HUMAN; PLATINUM DERIVATIVE; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; DNA MICROARRAY; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATINUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84907916718     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1096     Document Type: Article

References (42)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
3. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
4. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M,Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
5. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
6. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1, and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
7. Awad MM, Engelman JA, Shaw AT. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013;369:1173.
8. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.
9. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small cell lung cancer. J Clin Oncol 2013;31:1097-104.
10. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 2013;104:1396-400.
11. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
12. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285-91.
13. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
14. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12:99-110.
15. Kasinski AL, Slack FJ. Epigenetics and genetics. microRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011;11:849-64.
16. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
17. Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011;30:20.
18. Dong Z, Zhong Z, Yang L, Wang S, Gong Z. microRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 2014;343:249-57.
19. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-803.
20. Li Y, Li L, Guan Y, Liu X, Meng Q, Guo Q. miR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non-small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 2013;440: 604-10.
21. Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM. Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp Cell Res 2013;319:566-74.
22. Song L, Li Y, Li W,WuS, Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of coppertransporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 2014;115:1234-42.
23. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011;37:427-34.
24. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:8288-98.
25. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 2014;134:1926-34.
26. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011;17:1875-82.
27. Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 2013;73:3821-32.
28. Schetter AJ, LeungSY,Sohn JJ, Zanetti KA,BowmanED, Yanaihara N, et al. microRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
29. . Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. microRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192-200.
30. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010;16:5824-34.
31. Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2013;132:2901-9.
32. Hummel R, Hussey DJ, Haier J. microRNAs: predictors and modifiers of chemo-and radiotherapy in different tumour types. Eur J Cancer 2010;46:298-311.
33. Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer 2013;82:340-5.
34. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, et al. MicroRNA 92a-2-: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010;5:1273-8.
35. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small cell lung cancer. J Clin Oncol 2010;28:4945-52.
36. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-62.
37. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012;72: 100-11.
38. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, et al. Clinicopathological features of non-small cell lung carcinomas with BRAF mutations. Ann Oncol 2014;25:138-42.
39. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010;18:548-51.
40. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
41. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
42. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012;7:195.